BioSpace News Archive

Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca

Fortress Biotech, Inc., an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.

Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.

TG Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2019 and recent company developments.

3rd Quarter Revenue of $1,301 Million, compared to $1,373 Million, Net Loss of $177 Million, compared to Net Income of $0.2 Million, Adjusted EBITDA of $11.5 Million, compared to $41.9 Million

Phio Pharmaceuticals Corp. reported its financial results for the third quarter ended September 30, 2019 and provided a business update.

Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief executive officer, will present at the following investor conferences:

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, will participate in the Stifel 2019 Healthcare Conference in New York City.

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced the appointment of Maiken Keson-Brookes as chief legal officer and corporate secretary.